

Endogenous targeting: Elucidating the impact of the protein corona on lipid nanoparticle organ-targeting outcomes

Daniel J. Siegwart, Ph.D.

Department of Biomedical Engineering
Department of Biochemistry
Simmons Comprehensive Cancer Center

UT Southwestern
Medical Center


Conflict of interest disclosures



mRNA can be thought of as cellular software to encode a cornucopia of proteins to prevent or treat disease

mRNA can be thought of as cellular software to encode a cornucopia of proteins to prevent or treat disease

Personalized Cancer Vaccines




Lorentzen et al. *Lancet Oncol.* 23, e450 (2022).


Perez-Garcia et al. *Mol. Ther. Nucleic Acids* 28, 87 (2022).

mRNA can be thought of as cellular software to encode a cornucopia of proteins to prevent or treat disease

Personalized Cancer Vaccines



Protein Replacement Therapy




Lorentzen et al. *Lancet Oncol.* 23, e450 (2022).


Perez-Garcia et al. *Mol. Ther. Nucleic Acids* 28, 87 (2022).

mRNA can be thought of as cellular software to encode a cornucopia of proteins to prevent or treat disease


Personalized Cancer Vaccines



Protein Replacement Therapy



Genome Editing




Lorentzen et al. *Lancet Oncol.* 23, e450 (2022).


Perez-Garcia et al. *Mol. Ther. Nucleic Acids* 28, 87 (2022).

Gillmore et al. *New. Engl. J. Med.* 385, 493 (2021).


Lipid nanoparticles (LNPs) are used to overcome barriers that hinder the medical use of mRNA and genome editors



Lipid nanoparticles (LNPs) are used to overcome barriers that hinder the medical use of mRNA and genome editors



Local delivery barriers are also present and unique to specific sites





Hou, Zaks, Langer, Dong. **Nat. Rev. Mater.** 6, 1078 (2021).




Selo et al. **Adv. Drug. Deliv. Rev.** 177, 113862 (2021).

Juntila, de Sauvage. **Nature** 501, 346 (2013).



Local delivery barriers are also present and unique to specific sites



Local delivery barriers are also present and unique to specific sites



Local delivery barriers are also present and unique to specific sites



Hou, Zaks, Langer, Dong. **Nat. Rev. Mater.** 6, 1078 (2021).


Selo et al. **Adv. Drug. Deliv. Rev.** 177, 113862 (2021).

Junttila, de Sauvage. **Nature** 501, 346 (2013).


Extrahepatic (non-liver) delivery represents a major hurdle for LNPs




Extrahepatic (non-liver) delivery represents a major hurdle for LNPs




Passive, active, and endogenous mechanisms can enable nanoparticle targeting




Passive, active, and endogenous mechanisms can enable nanoparticle targeting




Passive, active, and endogenous mechanisms can enable nanoparticle targeting



Liver anatomy permits passive accumulation of nanoparticles




Proteins involved in transport of endogenous lipid particles through the blood direct LNPs to liver hepatocytes



Low-density lipoprotein


Lipid nanoparticle




Alteration of lipid molar ratios is necessary for efficient delivery of different nucleic acid cargoes but still results in hepatic delivery

Traditional LNP

Ionizable cationic lipid



Zwitterionic phospholipid



Cholesterol



PEG lipid




(fixed internal ratios)

siRNA formulations: Zhou et al. **PNAS** 113, 520 (2016).

mRNA formulations: Cheng et al. **Adv. Mater.** 30, 1805308 (2018).

Alteration of lipid molar ratios is necessary for efficient delivery of different nucleic acid cargoes but still results in hepatic delivery




siRNA formulations: Zhou et al. **PNAS** 113, 520 (2016).

mRNA formulations: Cheng et al. **Adv. Mater.** 30, 1805308 (2018).


Alteration of lipid molar ratios is necessary for efficient delivery of different nucleic acid cargoes but still results in hepatic delivery

Traditional LNP

Ionizable cationic lipid




Zwitterionic phospholipid




Cholesterol



PEG lipid




(fixed internal ratios)




Starting siRNA formulation


Cationic lipid
Phospholipid
Cholesterol
DMG-PEG



Optimized mRNA formulation



0.2 0.4 0.6 0.8 1.0
 $\times 10^8$



Saturated Luminescence


0.2 0.4 0.6 0.8 1.0
 $\times 10^8$

siRNA formulations: Zhou et al. **PNAS** 113, 520 (2016).


mRNA formulations: Cheng et al. **Adv. Mater.** 30, 1805308 (2018).

Selective ORgan Targeting (SORT) allows lipid nanoparticles (LNPs) to be systematically and predictably engineered to accurately edit cells in specific organs


SORT Lipid **Traditional LNP**




SORT allows LNPs to be systematically and predictably engineered to accurately edit cells in specific organs



SORT allows LNPs to be systematically and predictably engineered to accurately edit cells in specific organs



SORT allows LNPs to be systematically and predictably engineered to accurately edit cells in specific organs




Cheng et al. *Nat. Nanotechnol.* 15, 313 (2020).

Wei et al. *Nat. Commun.* 11, 3232 (2020).


Lee et al. *Angew. Chem. Int. Ed.* 60, 5848 (2021).

Liu et al. *Nat. Mater.* 20, 701-710 (2021).

Inclusion of a permanently cationic lipid into 5A2-SC8 LNPs systematically shifted luciferase protein as a function of SORT lipid percentage




DOTAP




5A2-SC8/DOPE/Chol/DMG-PEG/DOTAP = 15/15/30/3/X
where X = 0 – 1200 (mol/mol)

0.1 mg/kg Luc mRNA, IV, 6h


Inclusion of an anionic lipid completely switched luciferase protein expression from liver to spleen



18PA




Luminescence (p/sec/cm²/sr)




5A2-SC8 SORT LNPs
0.1 mg/kg Luc mRNA, IV, 6h

Interestingly, inclusion of ionizable cationic SORT lipids enhanced liver delivery




5A2-SC8 SORT LNPs
0.1 mg/kg Luc mRNA, IV, 6h


Three essential dogmas have been established for liver delivery of LNPs



1. Liver biodistribution




2. $pK_a = 6.4$




3. ApoE adsorption


Liver, Spleen, and Lung SORT LNPs were formulated and characterized




Liver, Spleen, and Lung SORT LNPs were formulated and characterized



SORT molecules promote biodistribution to the target organ but biodistribution is not sufficient for tissue-specific mRNA activity




SORT LNP pK_a correlates with organ-specific efficacy



67 distinct SORT LNPs, all with high *in vivo* delivery efficacy

Global/apparent LNP pKa measured by the 6-(*p*-toluidino)-2-naphthalenesulfonic acid (TNS) assay


SORT LNP pK_a correlates with organ-specific efficacy



67 distinct SORT LNPs, all with high *in vivo* delivery efficacy

Global/apparent LNP pK_a measured by the 6-(*p*-toluidino)-2-naphthalenesulfonic acid (TNS) assay


SORT LNP pK_a correlates with organ-specific efficacy




67 distinct SORT LNPs, all with high *in vivo* delivery efficacy

Global/apparent LNP pK_a measured by the 6-(*p*-toluidino)-2-naphthalenesulfonic acid (TNS) assay







We hypothesize that SORT LNPs also use an “**endogenous targeting**” mechanism via adsorption of different proteins



Does PEG-lipid desorption impact SORT LNP activity?




Replacing C14-PEG2K with slower shedding C18-PEG2K impairs mRNA delivery




0.1 mg/kg mRNA


Do SORT LNPs have distinct protein corona compositions?




Density gradient centrifugation was used to isolate the protein corona of SORT LNPs incubated in plasma *ex vivo*




The choice of SORT molecule yields a unique protein corona



The choice of SORT molecule yields a unique protein corona




The choice of SORT molecule yields a unique protein corona




The functional composition of the protein corona depends on the choice of SORT molecule

mDLNP




Liver
SORT




- Apolipoproteins
- Coagulation Proteins
- Complement Proteins
- Immune Proteins
- Other

The functional composition of the protein corona depends on the choice of SORT molecule


mDLNP




Liver
SORT



Spleen
SORT





Lung
SORT







- Apolipoproteins
- Coagulation Proteins
- Complement Proteins
- Immune Proteins
- Other

The serum proteins which most avidly bind an LNP depends on the chemical structure of a given SORT molecule




n = 3, top 80% of all adsorbed plasma proteins

The serum proteins which most avidly bind an LNP depends on the chemical structure of a given SORT molecule




n = 3, top 80% of all adsorbed plasma proteins

Do bound serum proteins impact receptor-mediated uptake and delivery?







Key proteins selectively enhance SORT LNP uptake and delivery to cells highly expressing their cognate receptor







Key proteins selectively enhance SORT LNP uptake and delivery to cells highly expressing their cognate receptor

Liver SORT
HuH-7 Cells







Spleen SORT
THP-1 Cells







Key proteins selectively enhance SORT LNP uptake and delivery to cells highly expressing their cognate receptor





Liver SORT
HuH-7 Cells




Spleen SORT
THP-1 Cells




Lung SORT
A-498 Cells




Does the inclusion of a SORT molecule impact ApoE-dependent delivery?




Extrahepatic mRNA delivery occurs via an ApoE-independent mechanism




Extrahepatic mRNA delivery occurs via an ApoE-independent mechanism




Extrahepatic mRNA delivery occurs via an ApoE-independent mechanism



Extrahepatic mRNA delivery occurs via an ApoE-independent mechanism




A library of permanently cationic quaternary ammonium lipids were incorporated into LNPs as SORT molecules at 50 mol. %



18:1 TAP


A library of permanently cationic quaternary ammonium lipids were incorporated into LNPs as SORT molecules at 50 mol. %

TAP Series



A library of permanently cationic quaternary ammonium lipids were incorporated into LNPs as SORT molecules at 50 mol. %

TAP Series



14:0 TAP


16:0 TAP

18:0 TAP

18:1 TAP

18:1 RI

EPC Series



12:0 EPC

14:0 EPC

16:0 EPC


18:0 EPC

18:1 EPC


16:0/18:1 EPC

All quaternary ammonium SORT molecules enable mRNA delivery to the lungs via intravenous administration


mDLNP




All quaternary ammonium SORT molecules enable mRNA delivery to the lungs via intravenous administration




All quaternary ammonium SORT molecules enable mRNA delivery to the lungs via intravenous administration




SORT molecule chemical structure impacts both the potency and tissue-selectivity of mRNA delivery




SORT molecule chemical structure impacts both the potency and tissue-selectivity of mRNA delivery




Differences in SORT molecule chemical structure within the same biophysical class can impact the composition of the protein corona




Different SORT molecules alter the identities and quantities of corona proteins




Alterations in protein corona are correlative with delivery outcomes



Alterations in protein corona are correlative with delivery outcomes




Alterations in protein corona are correlative with delivery outcomes




Key findings:

SORT molecules shift LNP biodistribution to the target organ




Key findings:

SORT molecules shift LNP biodistribution to the target organ




Distinct protein coronas enable endogenous targeting of specific organs




Dilliard et al. *Submitted, in revision.*
Wang et al. **Nat. Protocols** 18, 265 (2023).

Key findings:


SORT molecules shift LNP biodistribution to the target organ



Chemical features of SORT molecules impact the potency and selectivity of mRNA delivery




Distinct protein coronas enable endogenous targeting of specific organs




Dilliard et al. *Submitted, in revision.*
Wang et al. *Nat. Protocols* 18, 265 (2023).

Key findings:


SORT molecules shift LNP biodistribution to the target organ




Distinct protein coronas enable endogenous targeting of specific organs



Chemical features of SORT molecules impact the potency and selectivity of mRNA delivery



Multiple proteins appear to modulate delivery outcomes by affecting targeting of the lungs or de-targeting of the liver



Dilliard et al. Submitted, in revision.
Wang et al. **Nat. Protocols** 18, 265 (2023).

Acknowledgements



Lukas Farbiak



Sumanta Chatterjee



Pratima Basak



Ester Alvarez Benedicto



Xiaoyan Bian




Sean Dilliard



Erick Guerrero



Lisa Kim



Minjeong Kim



Xizhen Lian



William Miller



Stephen Moore



Joshua Robinson



Eunice Song




Yehui Sun



Yun-Chieh Sung



Amogh Vaidya




Xu Wang



Shiying Wu



Yufen Xiao



Zeru Tian



Yangyang Yang



Fangyu Zhang



Faaiz Enam


Funding:

National Institutes of Health, CPRIT, Cystic Fibrosis Foundation, Welch Foundation, ReCode Therapeutics

Collaborators:

Maddie Brown, Prof. Hao Zhu, Prof. Bruce Beutler, Prof. Eric Olson, Prof. Jonathan Cohen, Prof. Helen Hobbs

Acknowledgements




Funding:

National Institutes of Health, CPRIT, Cystic Fibrosis Foundation, Welch Foundation, ReCode Therapeutics

Collaborators:

Maddie Brown, Prof. Hao Zhu, Prof. Bruce Beutler, Prof. Eric Olson, Prof. Jonathan Cohen, Prof. Helen Hobbs

Acknowledgements



Funding:

National Institutes of Health, CPRIT, Cystic Fibrosis Foundation, Welch Foundation, ReCode Therapeutics

Collaborators:

Maddie Brown, Prof. Hao Zhu, Prof. Bruce Beutler, Prof. Eric Olson, Prof. Jonathan Cohen, Prof. Helen Hobbs